Twilight Litaka Pharma Limited
Regd. Office : B-22, 'H' BLOCK, MIDC PIMPRI, PUNE-411018

PART I

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST MAR, 2013

(Rs.In Lac)

S No.	Particulars	Quarter Ended			Year to Date		Previous Year ended
		(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Audited)
		31.03.2013	31.12.2012	31.03.2012	31.03.2013	31.03.2012	31.03.2012
1	a. Net Sales / Income From Operations	2029.12	5586.63	17925.03	32644.54	73018.65	73018.65
	b. Other Operating Income						
2	Expenditure						
	a Increase/decrease in stock in trade & WIP	-121.15	188.83	-136.36	421.84	-276.52	-276.52
	b Consumption of Raw material	1074.12	2493.87	1504.13	15299.23	40054.81	40054.81
	c Purchase of traded goods.	475.21	1851.97	12931.22	10200.57	16402.58	16402.58
	d Employee cost	156.19	158.10	469.02	1022.90	1998.63	1998.63
	e Depreciation	126.44	128.88	127.94	523.91	510.51	510.51
	f Other expenditure	3327.78	501.12	4546.31	5793.35	7983.53	7983.53
	g Expenditure (a to f)	5038.59	5322.77	19442.27	33261.80	66673.54	66673.54
3	Profit from Operations before Other Income, Interest and Exceptional Items (1-2)	-3009.47	263.86	(1517.24)	-617.26	6345.11	6345.11
4	Other Income	9.25	10.24	26.91	53.34	104.40	104.40
5	Profit before Interest & Exceptional Items (3+4)	-3000.22	274.10	(1490.33)	-563.92	6449.51	6449.51
6	Interest	-2685.87	1013.27	1036.22	783.21	4502.39	4502.39
7	Profit/(Loss) after Interest, but before Exceptional Items (5-6)	(314.35)	(739.17)	(2526.56)	(1,347.13)	1947.12	1947.12
8	Exceptional Items			(1503.07)	-	(1,503.07)	(1,503.07)
9	Profit/(Loss) from Ordinary Activities before tax (7+8)	(314.35)	(739.17)	(4029.62)	(1,347.13)	444.05	444.05
10	Tax Expenses		0.00	1178.00	0.00	92.00	92.00
11	Profit/(Loss) from Ordinary Activities after tax (9-10)	(314.35)	(739.17)	(2851.62)	(1,347.13)	352.05	352.05
12	Extraordinary items (net of tax expense)						
13	Net Profit/(Loss) for the period	(314.35)	(739.17)	(2851.62)	(1,347.13)	352.05	352.05
14	Paid-up Equity Share Capital (Equity share of Rs.5/- each)	1239.06	1239.06	1239.06	1239.06	1239.06	1239.06
15	Reserve excluding revaluation reserves	14315.32	18394.26	16345.22	14998.09	16345.22	16345.22
16	Earning per share (EPS)						
	a. Basic and diluted EPS before extraordinary items for the period	(1.27)	(2.98)	(11.51)	(5.44)	*1.42	*1.42
	b. Basic and diluted EPS after extraordinary items for the period.	(1.27)	(2.98)	(11.51)	(5.44)	*1.42	*1.42
II	INFORMATION FOR THE QUARTER ENDED 31.03.2013						
A	PARTICULARS OF SHAREHOLDING						
1	Aggregate of non promoter shareholding						
	number of shares	24464849	23683261	23520796	24464849	23520796	23520796
	percentage of shareholding	98.72	95.57	94.91	98.72	94.91	94.91
2	Promoters and Promoters Group shareholding						
	a) Pledged / Encumbered						
	- Number of shares	15350	796938	1236247	15350	1236247	1236247
	- Percentage of shares (as % to the total shareholding of promoters & promoters group)	4.85	72.58	98.07	4.85	98.07	98.07
	- Percentage of shares (as % to the total share capital of the Company)	0.06	3.22	4.99	0.06	4.99	4.99
	b) Non Encumbered						
	- Number of shares	301086	301086	24242	301086	24242	24242
	- Percentage of shares (as % to the total shareholding of promoters & promoters group)	27.42	27.42	1.93	27.42	1.93	1.93
	- Percentage of shares (as % to the total share capital of the Company)	1.21	1.21	0.10	1.21	0.10	0.10

* not annualised

Particulars	3 months ended 31/03/2013
INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	17
Received during the quarter	3
Disposed of during the quarter	19
Remaining unresolved at the end of the quarter	1

Notes :

1] The above unaudited results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 15th May, 2013.

2] The Company is primarily engaged in Pharmaceutical formulations business, which in the context of Accounting Standard (AS17) "Segment Reporting" is considered to be the only business segment.

3] The financial results for the quarter and Twelve months ended on 31st March,2013 of the company are prepared on standalone basis.

4] The company is making efforts to overcome the present critical financial position by disposing / developing some of its non core assets. The sale proceeds of these assets will be utilized in reducing bank liabilities and also it will meet urgent requirements of working capital. In view of this your directors are optimistic that your company will be in position to turn the corner in the current financial year. And on this basis the management is of view that it continues to operate as a going concern and have ability to fully meet its financial obligations.

5] The Company's Bank accounts became NPA and consequently no interest provision has been made in the books from that date. Provision made earlier has also being reversed. Some of the banks have issued notices under SARFAISI ACT 2002 and also filed suits in DRT. Some of the creditors of the company have filed windig up petitions

6] The Board of Directors of the Company has approved the proposal to extend Company's current Financial year i.e. 2012-13 by a period up to Three months i.e. up to 30th June, 2013. Accordingly the said financial year will be for a period of 15 months ending

7] The Board of Directors of the Company in its meeting held on 15th May, 2013 has approved the proposal to deal, negotiate or dispose off the whole or part of the Company's manufacturing unit located at Baddi Dist. Solan Himachal Pradesh.

8] The above results were subject to Limited Review by the Statutory Auditors of the Company pursuant to Clause 41 of the Listing Agreement.

9] Previous year's figures have been regrouped and rearranged wherever necessary.

For TWILIGHT LITAKA PHARMA LIMITED

GOPAL RAMOURTI
Managing Director

Place : Pune
Date : 15/05/2013